Abstract
The analysis of synovial biomarkers is increasingly used in the context of innovative trial design in rheumatoid arthritis (RA). This approach, which is generally well tolerated by patients, has been used to provide insight into the pathogenesis of RA and the mechanism of action of therapy, as well as for screening purposes during early drug development.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Murine-Derived
-
Antirheumatic Agents / therapeutic use*
-
Arthritis, Rheumatoid / drug therapy*
-
Arthritis, Rheumatoid / immunology
-
Biomarkers
-
Chemokines / drug effects
-
Humans
-
Rituximab
-
Synovial Membrane / drug effects*
-
Synovial Membrane / immunology
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Antirheumatic Agents
-
Biomarkers
-
Chemokines
-
Tumor Necrosis Factor-alpha
-
Rituximab